Clearside Biomedical (NASDAQ:CLSD) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is a 35.29 percent increase over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $2.33 million which beat the analyst consensus estimate of $170.00 thousand by 1.27K percent. This is a 913.04 percent increase over sales of $230.00 thousand the same period last year.